LynxKite

What LynxKite does

LynxKite is an independent AI platform company providing GPU-accelerated graph analytics, graph neural network (GNN), knowledge graph, and LLM orchestration tooling primarily for pharmaceutical R&D teams. Spun off from Lynx Analytics on March 1, 2026 after originating inside the parent founded in Singapore in 2012, the company is headquartered in Singapore with offices in Cambridge, Massachusetts and Switzerland. Its flagship product, LynxKite 2000:MM, is a no-code, composable AI orchestration platform that integrates NVIDIA BioNeMo, cuGraph, RAPIDS, RDKit, and PyKEEN to run multimodal, agentic workflows at GPU scale for use cases spanning target discovery, indication selection, in-silico compound screening, pharmacokinetic modeling, and clinical trial optimization.

The technology stack combines more than 600 graph algorithms (100+ GPU-accelerated), a proprietary GNN architecture designer with attention-based explainability, GraphRAG capabilities, an LLM Training Plugin supporting LoRA, SFT, and GRPO, and pre-trained biomolecular models for drug discovery. LynxKite serves a blue-chip enterprise base that includes Roche, AstraZeneca, Sanofi, Amgen, Novo Nordisk, MIT, Singapore's Land Transport Authority, and biotech partners such as Biophytis, Hummingbird Bioscience, and Cytovia. The platform is distributed under GNU AGPLv3 open source for community adoption through GitHub and pip, while commercial access to LynxKite 2000:MM is sold directly or via the legacy Lynx Analytics licensing channel.

LynxKite operates a hybrid go-to-market model combining product-led open-source adoption, targeted enterprise sales for pharmaceutical verticals, and consulting-led implementation services. Revenue streams include commercial licensing of LynxKite 2000:MM, professional services and consulting engagements, and revenue-generating drug discovery partnerships such as the expanded Biophytis MASSIVE program for sarcopenia and dry age-related macular degeneration, which is supported by Singapore's Enterprise Singapore. The company has 100+ enterprise customers globally; headcount and revenue are not publicly disclosed, and no venture funding rounds have been reported in the available sources.

Name

LynxKite

Legal name

LynxKite Technologies Pte Ltd

Website

https://lynxkite.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

LynxKite is an independent AI platform company that provides GPU-accelerated graph analytics, graph neural networks, knowledge graph, and LLM orchestration tools, primarily serving pharmaceutical R&D and enterprise data science teams at major pharma and biotech companies.

Ownership category

akta.pro rank

Product category

Graph AI and Drug Discovery Platform

NAICS

Software Publishers (513210), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (5415), Other Computer Related Services (541519)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI) (HDAEANAI)

akta.pro secondary industries

Model Development & Training Platforms (AutoML, Notebooks, Feature Stores) (HDAEANAB), End-to-End MLOps & ML Platform Suites (HDAAABAA), Industry/Domain Analytics Solutions & Accelerators (BPAEAHAK), iBPMS (Intelligent BPM Suites) & Process Automation Suites (HDAEAHAG)

Keywords

• Graph analytics platform
• Drug discovery AI
• Graph neural networks
• Knowledge graph platform
• AI workflow orchestration

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Drug discovery platform services: Revenue generation through computational longevity platform with curated datasets and accelerated computation methods for longevity research. Partnership with Biophytis generates revenue from drug candidate development.
2. Consulting and implementation services: Tailored consulting services to implement LynxKite in analytics environments and accelerate learning curve. Previously part of Lynx Analytics services business.
3. Commercial licensing: Commercial license of LynxKite 2000:MM offered by Lynx Analytics that includes additional features and support for life sciences tools and cluster deployment.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

LynxKite builds and sells LynxKite 2000:MM, a GPU-accelerated, composable AI orchestration platform that combines graph analytics, graph neural networks (GNNs), knowledge graphs, LLM agent workflows, and NVIDIA BioNeMo for preclinical and early-stage pharmaceutical pipelines. The platform provides a no-code drag-and-drop workflow builder with multimodal data support (omics, clinical trials, molecular structures), 600+ graph algorithms (100+ GPU-accelerated via cuGraph), and one-click GPU deployment. A legacy open-source Apache Spark-based LynxKite product is also offered for enterprise graph analytics.

Product overview

LynxKite offers a unified product portfolio centered on LynxKite 2000:MM as the primary composable AI orchestration platform for drug discovery and enterprise analytics. This core platform incorporates specialized environments for graph analytics (with 600+ algorithms) and PyTorch neural network design. The portfolio also includes a legacy Spark-based LynxKite for organizations requiring Apache Spark integration, and the LynxKite LLM Training Plugin extending capabilities for fine-tuning large language models without code. The products share a common visual workflow builder, GPU acceleration via NVIDIA technologies, and knowledge graph foundations, while serving both life sciences (drug discovery, biomarker analysis) and enterprise use cases (fraud detection, customer analytics).

Differentiator

Problem solved

Functional benefit

Products and services

• LynxKite 2000:MM A composable AI orchestration platform for preclinical and early-stage pharmaceutical pipelines, combining biomedical knowledge graphs, NVIDIA BioNeMo, and open ecosystems for multimodal, agentic workflows at GPU scale—from target discovery to candidate prioritization. Features drag-and-drop workflow design, a graph-native interface, and one-click GPU deployment. Sold via enterprise direct sales and consulting services, with a commercial license channel.
• LynxKite (Spark-based) Open-source graph data science platform based on Apache Spark for enterprise graph analytics and Graph AI. Provides a graph operations library, machine learning pipelines, and a no-code GUI combined with Python integration for citizen data scientists. Distributed via GitHub and pip under GNU AGPLv3.

Quantifiable outcome

• Clinical trial optimization can reduce time to approval by up to 2 years
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration14 records

AI capability14 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered supporting, core and flagship.

• AccenturesupportingStrategic or Co-development Partner · 30 April 2026Co-presented at NVIDIA GTC 2026 with Biophytis and Nebius to demonstrate integrated AI-driven drug discovery approach combining biological insight, graph-based AI workflows, and scalable GPU infrastructure.
• BiophytiscoreStrategic or Co-development Partner · 13 March 2026Expanded strategic partnership starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) targeting sarcopenia and expanding to dry age-related macular degeneration. The collaboration combines Biophytis' expertise in age-related diseases with LynxKite's AI platform, graph analytics, and GPU computation to accelerate longevity drug discovery. Generates revenue through computational longevity platform and drug candidate development.
• Enterprise SingaporeflagshipStrategic or Co-development Partner · 13 March 2026Singapore government agency supporting the Biophytis-LynxKite partnership. Supports innovation and enterprise development aligned with Singapore's Research, Innovation and Enterprise (RIE) 2030 plan. Provides funding and strategic support for longevity therapeutics AI platform development.
• NebiussupportingTechnology or Integration · 13 March 2026AI cloud company providing GPU computation infrastructure for the partnership. Nebius provides scalable GPU resources and HPC time for running complex drug discovery pipelines on NVIDIA toolkits.
• NVIDIAcoreTechnology or Integration · 3 March 2026NVIDIA Inception Premier partner. LynxKite integrates with NVIDIA RAPIDS, cuGraph, BioNeMo, and NIM Microservices. GPU-accelerated platform built on NVIDIA accelerated computing for graph AI and generative AI applications. LynxKite participates in Inception program for startups with access to Deep Learning Institute credits, marketing support, and technology assistance.
• Neo4jsupportingTechnology or IntegrationGraph database partnership. LynxKite can import data from Neo4j and complements graph database technology with graph data science and AI capabilities.
• DatabrickssupportingTechnology or IntegrationData analytics platform integration. Supports data import and workflow orchestration with Databricks environment.
• AWSsupportingTechnology or IntegrationAmazon Web Services cloud partnership. LynxKite supports deployment on AWS cloud infrastructure.
• Microsoft AzuresupportingTechnology or IntegrationAzure cloud platform partnership. LynxKite supports deployment on Microsoft Azure cloud infrastructure.
• Google Cloud PlatformsupportingTechnology or IntegrationGCP cloud partnership. LynxKite supports deployment on Google Cloud Platform infrastructure.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Databricks: Databricks provides a broad lakehouse + ML/AI platform that includes graph capabilities (via integrations and the GraphFrames library) and is already a core integration partner for LynxKite. It is a broader platform incumbent that overlaps with LynxKite in pharma and enterprise data-science workloads.
• DataRobot: DataRobot offers an enterprise AutoML and MLOps platform with time-to-value and governance messaging comparable to LynxKite's no-code AI workflow story. It serves regulated industries and competes for similar pharma and financial-services AI budgets.
• AWS Neptune: AWS Neptune is a managed graph-database service native to a hyperscaler ecosystem. Combined with SageMaker, it competes with LynxKite for enterprise graph-AI workloads and benefits from AWS distribution while LynxKite also runs on AWS.
• Palantir Technologies: Palantir Foundry and AIP offer enterprise AI/data platforms used by several of the same large pharma customers (e.g., industry players in clinical operations) that LynxKite counts as users, representing an incumbent alternative for pharma R&D data integration and AI workflows.

Direct peers

• Stardog: Stardog is a knowledge-graph platform that combines enterprise data virtualisation, reasoning, and ML to support AI applications — a directly comparable graph-AI stack for pharma and enterprise use cases that LynxKite targets.
• Neo4j: Neo4j offers a native graph database with a Graph Data Science library (graph algorithms, ML embeddings) that competes directly with LynxKite's graph analytics and GNN capabilities. Both target enterprise data-science teams for connected-data analytics; LynxKite's open-source repo explicitly integrates with Neo4j as a data source.
• TigerGraph: TigerGraph provides an enterprise graph database and analytics platform with ML and Graph Data Science features comparable to LynxKite's graph-analytics environment. It targets similar financial services, healthcare, and enterprise buyers needing relationship analytics at scale.
• RelationalAI: RelationalAI combines a graph-relational data model with AI/ML workloads in the cloud, mirroring LynxKite's graph-native AI positioning. Both companies pitch a knowledge-graph-plus-ML foundation for enterprise AI applications.

Emerging players

• Anaconda: Anaconda provides a data-science platform and package distribution used by the same open-source, Python-first developer audience that installs LynxKite via pip. It is an adjacent competitor in the open-source Python data/AI tooling layer.

Others

• NVIDIA (BioNeMo / NIM): NVIDIA is both a core technology partner and an adjacent platform: BioNeMo, RAPIDS, cuGraph, and NIM microservices underpin LynxKite, while NVIDIA could also expand higher-level orchestration that competes with LynxKite's positioning as the graph-native AI layer above those primitives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• GitHubgithub.com/lynxkite/lynxkite-2000
• Xx.com/LynxKite
• LinkedInlinkedin.com/company/lynxkite

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LynxKite